Coronavirus / COVID

People with rheumatologic conditions are more likely to experience COVID-19 symptoms lasting longer than a month, and this is affected by smoking or preexisting conditions.

Interim, unpublished data show PAXLOVID is associated with 89% reductions in risk of COVID-19 hospitalization or death. Pfizer is now seeking FDA emergency authorization.

The Biden administration is also setting mandates for health care workers in facilities receiving federal aid.

The investigational oral antiviral therapy from Merck is still awaiting FDA authorization.

Novavax was approved for their first COVID-19 vaccine EUA in Indonesia, and expects more to follow shortly.

The ACIP considered the benefits of the newly emergency-authorized vaccine versus the risks of COVID-19 in children aged 5-11 years old.

Loma Linda University worked with local leaders to help promote equitable delivery of COVID-19 vaccines in Black communities.

Pilot program benefits those in need most, covering potential costs associated with vaccination.

The monoclonal antibody sotrovimab reduced the risk of hospitalization or death by 85% in high-risk patients with mild-to-moderate COVID-19.

The emergency use authorization (EUA) is based on the vaccine data and the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation.

A new report underscores what early data suggested about disparities in the risk of hospitalization and death from COVID-19.

COVID-19 patients treated with fluvoxamine had a reduced risk of hospitalization and death.

Most COVID-19 infection occurs in household settings, and though vaccinated individuals who contracted the Delta variant recovered more quickly than unvaccinated persons, they had similar peak viral load.

The new AY.4.2 "Delta plus" COVID-19 variant is gaining prevalence abroad and is estimated to be slightly more transmissible.

A new study assessed the vaccine acceptance and access among Black and Latinx communities.

First responders are twice as likely to become infected with COVID-19 in the workplace as health care workers and other essential workers, and this increases significantly after adjusting for cofounding factors.

The World Health Organization's (WHO) newly formed Scientific Advisory Group on the Origins of Novel Pathogens (SAGO) will lay the groundwork for future identification of future disease threats.

St. Joseph Mercy Health System launched a program in February to provide infusion of monoclonal antibodies for COVID-19 in patients’ homes.

This recommendation was based off of data showing the vaccine was 90% efficacious in this population, and sets the stage for the first COVID-19 vaccine in the age group.

The committee is meeting today to review the data presented to them, and will vote to either recommend or not an Emergency Use Authorization in this pediatric population.

Investigators retrospectively observed 2 communities of essential workers in Toronto, Canada.

Unpublished data from the company's ongoing pediatric trial show children aged 6 to <12 years old have an antibody response greater than that of young adults.

The median vaccination rate of white American adults was found to be 1.3 times higher than Black and Hispanic adults.

Data presented to the Vaccines and Related Biological Products Advisory Committee (VRBPAC) showed 2 10 µg doses of the Pfizer-BioNTech vaccine to be 90.7% effective in children older than 5 and younger than 12.

The federal agency and infectious disease organization have teamed up to offer a wealth of resources for health care professionals on the frontlines of treating the virus.

The FDA and CDC have authorized and recommended 3 different booster doses, to be used in "mix-and-match" strategy among eligible adults. What does this mean for immunity?

The Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky's, MD, endorsement Thursday evening came after 2 days of deliberation from the CDC’s Advisory Committee on Immunization Practices (ACIP) where the group recommended the Moderna and Janssen COVID-19 vaccine “booster” doses.

The actions taken by the FDA set differing availability of the 3 emergency-authorized vaccines.

PASC (postacute sequelae of COVID-19) was found to persist for at least 6 months in more than half of those contracting the infection.

The CDC found 2 doses of Pfizer-BioNTech reduced COVID-19 severe outcomes and hospitalization by 93% in adolescents 12-18 years old.